Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of Delta SUVmax in the FDG-Avid Patients of the IMAJEM Study

Affiliation auteurs!!!! Error affiliation !!!!
TitreInterim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of Delta SUVmax in the FDG-Avid Patients of the IMAJEM Study
Type de publicationJournal Article
Year of Publication2018
AuteursBailly C, Carlier T, Jamet B, Eugene T, Touzeau C, Attal M, Hulin C, Facon T, Leleu X, Perrot A, Garderet L, Macro M, Caillot D, Moreau P, Kraeber-Bodere F, Bodet-Milin C
JournalCLINICAL CANCER RESEARCH
Volume24
Pagination5219-5224
Date PublishedNOV 1
Type of ArticleArticle
ISSN1078-0432
Résumé

{Purpose: To assess the prognostic value of interim F-18-fluorodeoxyglucose (FDG)-PET analysis using decrease in maximum standardized uptake value (SUVmax) versus visual analysis in patients with multiple myeloma. Patients and Methods: We evaluated the prognostic value of FDG-PET after three cycles of lenalidomide, bortezomib, and dexamethasone (RVD) in patients with FDG-avid multiple myeloma included in the French prospective multicenter IMAJEM study. All images were centrally reviewed and interpreted using visual criteria and maximal standardized uptake value reduction (DSUVmax). Known prognostic factors, such as the revised International Staging System and biochemical response after three cycles of chemotherapy, were also evaluated. Results: In the multivariate analysis, only DSUVmax [P < 0.001
DOI10.1158/1078-0432.CCR-18-0741